Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

No

•1. Participants who are 18 years or older
•2. Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH
•3. Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines
•4. Participants who per physician's criteria need to optimize their LLT
•5. Participants who provide written informed consent to participate in the study
•6. Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation.

•1. Participants that have received inclisiran previously
•2. Participants participating in a clinical trial with investigational product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)

Related studies

NCT06314919 · Primary Hypercholesterolemia, Mixed Dyslipidemia

NCT06932705 · Mixed Dyslipidemia

NCT06568471 · Hypercholesterolemia, Dyslipidemias, and more

NCT05621070 · Primary Hypercholesterolaemia and Mixed Dyslipidemia

NCT06497127 · Mixed Dyslipidemia

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD